Clinical Study to Evaluate the Possible Efficacy and Safety of Antibodies Combination (casirivimab and imdevimab) versus standard antiviral therapy as antiviral agent against Corona virus 2 infection in hospitalized COVID-19 patients

Ahmed H. Hassan, Sahar K. Hegazy, Samar T. Radwan
doi: https://doi.org/10.1101/2022.08.20.22279020

Data Availability

All data produced in the present work are contained in the manuscript

https://drive.google.com/drive/folders/1X1dDQwW9vBvusutwMbeebUjN8jJqYxsh?usp=sharing

Back to top
Posted February 23, 2023.
Download PDF
Data/Code
Email
Clinical Study to Evaluate the Possible Efficacy and Safety of Antibodies Combination (casirivimab and imdevimab) versus standard antiviral therapy as antiviral agent against Corona virus 2 infection in hospitalized COVID-19 patients
Ahmed H. Hassan, Sahar K. Hegazy, Samar T. Radwan
medRxiv 2022.08.20.22279020; doi: https://doi.org/10.1101/2022.08.20.22279020
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area